Fosamax is prescribed to treat osteoporosis, a disease that causes bones to deteriorate and break. It is a bisphosphonate, designed to reduce the activity of cells that cause the breakdown of bones. Fosamax is manufactured by Merck and Co. and was approved by the FDA in 1999.
Common side effects include gastrointestinal distress (e.g., nausea, stomach pain, constipation) and osteonecrosis of the jaw with severe pain or inflammation, loss of function and disfigurement. Osteonecrosis is the destruction of bone tissue and frequently leads to infection or fractures. Osteonecrosis of the jaw is not a common disease and therefore has been a major factor in cases brought against the drug. A class-action lawsuit was filed against Merck and Co. on April 10, 2006, alleging that Fosamax causes osteonecrosis of the jaw.
To learn more about legal claims relating to Fosamax, you should consult an attorney who practices in the area of drugs and medical devices.